Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

122.31 +0.73 (+0.60%)
Official Closing Price Updated: 7:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Glaukos Corp

< Previous 1 2 3 Next >
Glaukos Announces FDA 510(k) Clearance of iPRIME™
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos Corporation Announces Third Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.
From Glaukos Corporation
Via Business Wire
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
From Glaukos Corporation
Via Business Wire
Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies
From Glaukos Corporation
Via Business Wire
Glaukos Corporation Announces Second Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5
From Glaukos Corporation
Via Business Wire
Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule
From Glaukos Corporation
Via Business Wire
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR
From Glaukos Corporation
Via Business Wire
Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt
From Glaukos
Via Business Wire
Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference
From Glaukos Corporation
Via Business Wire
Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement
From Glaukos Corporation
Via Business Wire
Glaukos Corporation Announces First Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Announces the Release of its 2020 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia
From Glaukos Corporation
Via Business Wire
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5
From Glaukos Corporation
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.